Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

5.440 +0.070 (+1.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Navigating 11 Analyst Ratings For Bicycle Therapeutics ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Bicycle Therapeutics ↗
 
Via Benzinga
News headline image
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients ↗
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification. 
Via Benzinga
News headline image
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
BCYC: A Promising Play In The Biotech Sector ↗
The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a... 
Via Talk Markets
Topics ETFs
News headline image
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone ↗
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033... 
Via Benzinga
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
News headline image
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.